share_log

四環醫藥：自願公告-惠升生物研發的三款門冬胰島素系列產品在胰島素專項接續採購中獲得擬中選資格

SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-THREE PRODUCTS OF THE INSULIN ASPART SERIES DEVELOPED BY HUISHENG BIOPHARMACEUTICAL OBTAINED BID-WINNING QUALIFICATION IN THE SPECIALISING RENEWAL IN INSULIN PROCUREMENT

Hong Kong Stock Exchange ·  Apr 25 05:17
Summary by Moomoo AI
四環醫藥控股集團有限公司宣布，其非全資附屬公司惠升生物製藥股份有限公司的三款門冬胰島素系列產品在國家組織藥品聯合採購辦公室組織的全國藥品集中採購（胰島素專項接續）中獲得擬中選資格。這三款產品分別為門冬胰島素注射液、門冬胰島素30注射液和門冬胰島素50注射液，均於2023年12月26日獲得國家藥品監督管理局批准上市。此次中選將有助於惠升生物提高市場佔有率，加速產品准入，並對其品牌影響力及未來發展產生積極影響。惠升生物專注於糖尿病及併發症領域，已成為國內全產業鏈生物制藥公司。四環醫藥於2001年創立，2010年在香港聯合交易所有限公司主板上市，致力於成為中國領先的醫美及生物制藥企業。
四環醫藥控股集團有限公司宣布，其非全資附屬公司惠升生物製藥股份有限公司的三款門冬胰島素系列產品在國家組織藥品聯合採購辦公室組織的全國藥品集中採購（胰島素專項接續）中獲得擬中選資格。這三款產品分別為門冬胰島素注射液、門冬胰島素30注射液和門冬胰島素50注射液，均於2023年12月26日獲得國家藥品監督管理局批准上市。此次中選將有助於惠升生物提高市場佔有率，加速產品准入，並對其品牌影響力及未來發展產生積極影響。惠升生物專注於糖尿病及併發症領域，已成為國內全產業鏈生物制藥公司。四環醫藥於2001年創立，2010年在香港聯合交易所有限公司主板上市，致力於成為中國領先的醫美及生物制藥企業。
FOUR RING PHARMACEUTICAL HOLDINGS GROUP LIMITED ANNOUNCED THAT THREE MANDON INSULIN SERIES PRODUCTS OF ITS NON-WHOLLY OWNED SUBSIDIARY HEICHENG BIOPHARMACEUTICAL CO., LTD., ARE ELIGIBLE FOR SELECTION IN THE NATIONAL PHARMACEUTICAL POOL PROCUREMENT (INSULIN SPECIFIC CONTINUATION) OF THE NATIONAL PHARMACEUTICAL ORGANIZATION JOINT PROCUREMENT OFFICE OF THE NATIONAL PHARMACEUTICAL ORGANIZATION. The three products, namely Mondon Insulin Injection, Monton Insulin 30 Injection and Monton Insulin 50 Injection, were approved by the National Drug Administration on 26 December 2023. This by-election will help Booze Bios increase its market share, accelerate product entry, and positively impact its brand impact and future development. Focusing on diabetes and complications, Wellcome Biologics has become a domestic industry chain biopharmaceutical company. Founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010, Four Circle Pharmaceuticals is committed to becoming a leading pharmaceutical and biopharmaceutical company in China.
FOUR RING PHARMACEUTICAL HOLDINGS GROUP LIMITED ANNOUNCED THAT THREE MANDON INSULIN SERIES PRODUCTS OF ITS NON-WHOLLY OWNED SUBSIDIARY HEICHENG BIOPHARMACEUTICAL CO., LTD., ARE ELIGIBLE FOR SELECTION IN THE NATIONAL PHARMACEUTICAL POOL PROCUREMENT (INSULIN SPECIFIC CONTINUATION) OF THE NATIONAL PHARMACEUTICAL ORGANIZATION JOINT PROCUREMENT OFFICE OF THE NATIONAL PHARMACEUTICAL ORGANIZATION. The three products, namely Mondon Insulin Injection, Monton Insulin 30 Injection and Monton Insulin 50 Injection, were approved by the National Drug Administration on 26 December 2023. This by-election will help Booze Bios increase its market share, accelerate product entry, and positively impact its brand impact and future development. Focusing on diabetes and complications, Wellcome Biologics has become a domestic industry chain biopharmaceutical company. Founded in 2001 and listed on the main board of the Hong Kong Stock Exchange Limited in 2010, Four Circle Pharmaceuticals is committed to becoming a leading pharmaceutical and biopharmaceutical company in China.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more